查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1599692

mRNA 治疗市场：按类型、应用和最终用途 - 2025-2030 年全球预测

mRNA Therapeutics Market by Type (Prophylactic Vaccines, Therapeutic Drugs, Therapeutic Vaccines), Application (Infectious Diseases, Oncology, Rare Genetic Diseases), End Use - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023 年 mRNA 治疗市场价值为 338.2 亿美元，预计到 2024 年将达到 419.9 亿美元，复合年增长率为 24.65%，到 2030 年将达到 1582 亿美元。

mRNA疗法是指利用传讯RNA来引导细胞产生有助于治疗或预防疾病的蛋白质。这个快速发展的领域正在利用人类细胞中蛋白质合成的自然过程来解决各种健康状况，从像 COVID-19 这样的感染疾病到像癌症这样的非感染疾病。对 mRNA 疗法的需求在于其快速开发、可扩展性和多功能性的潜力，这些已经在使用有效疫苗对 COVID-19 大流行的快速反应中得到了证明。主要应用和终端市场包括免疫、癌症免疫治疗和罕见遗传疾病，为个人化医疗提供了广阔的前景。

主要市场统计
基准年[2023] 338.2亿美元
预测年份 [2024] 419.9亿美元
预测年份 [2030] 1,582亿美元
复合年增长率（%） 24.65%

mRNA 疗法的市场成长主要是由技术进步、公共和私人资金增加以及生物技术和製药公司之间的策略联盟所推动的。 mRNA 疫苗最近的成功激发了人们的兴趣和投资，为将基于 mRNA 的疗法扩展到感染疾病以外的领域提供了潜在机会。利用这些机会的建议包括投资强大的研发基础设施、建立策略联盟以及注重监管控制以促进市场进入。

阻碍市场开拓的挑战包括高昂的开发成本、由于 mRNA 固有的不稳定性而导致的复杂的储存和分配，以及证明长期安全性和有效性的监管障碍。此外，製造能力的限制和智慧财产权纠纷也是重大障碍。

创新和研究的目标应是优化 mRNA 稳定性和递送系统，提高靶向特定细胞和组织的精确度，并降低製造成本。市场动态的特征是快速的技术创新、激烈的竞争和高度动态的监管要求。与学术界和研究机构的合作可以提供宝贵的见解，并推动这一极具前景的领域的前瞻性策略。

市场动态：揭示快速发展的 mRNA 治疗市场的关键市场洞察

供需的动态交互作用正在改变 mRNA 治疗市场。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助消费行为及其对製造业的影响。

  • 市场驱动因素
    • 慢性病和感染疾病的盛行率增加
    • 对癌症疫苗和治疗的需求不断增长
    • 对 mRNA 疗法的需求激增以及政府对大规模定序计划的倡议
  • 市场限制因素
    • 高研究成本和 mRNA 定量失败的威胁
  • 市场机会
    • 生物技术研究与开发 (R&D)倡议的活性化以及医疗技术的进步
    • 透过强大的新产品系列开发个人化癌症治疗方法
  • 市场问题
    • mRNA 治疗的监管问题与策略

波特五力：引领 mRNA 治疗市场的策略工具

波特的五力框架是了解 mRNA 治疗市场竞争格局的关键工具。波特的五力框架描述了评估公司竞争和探索策略机会的清晰方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点，避免潜在的挑战，确保更强大的市场地位。

PESTLE分析：了解 mRNA 治疗市场的外部影响

外部宏观环境因素在塑造 mRNA 治疗市场的绩效动态发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析：了解 mRNA 治疗市场的竞争格局

对 mRNA 治疗市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示自己的竞争定位。该分析揭示了市场集中、细分和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵：mRNA 治疗市场供应商的绩效评估

FPNV定位矩阵是评估mRNA治疗市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议：绘製 mRNA 治疗市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对 mRNA 治疗市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

该报告对涵盖关键焦点细分市场的市场进行了全面分析。

1. 市场渗透率：对当前市场环境的详细审查，主要企业的广泛资料，评估他们在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有细分市场的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策。

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品和地区提供最佳投资机会？

3.塑造市场的关键技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 慢性病和感染疾病的发生率增加
      • 对癌症疫苗和治疗的需求增加
      • 对 mRNA 疗法的需求不断增长，政府对大规模定序计划的承诺不断增加
    • 抑制因素
      • 高研究成本和 mRNA 定量失败的威胁
    • 机会
      • 重大生物技术研发 (R&D)倡议与医疗技术进步
      • 透过强大的新产品系列开发个人化癌症治疗方法
    • 任务
      • mRNA 治疗的监管问题与策略
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 经济
    • 社会
    • 科技
    • 法律
    • 环境

第六章 mRNA 治疗市场：依类型

  • 介绍
  • 预防性疫苗
  • 治疗
  • 治疗性疫苗

第七章 mRNA 治疗市场：依应用分类

  • 介绍
  • 感染疾病
  • 肿瘤学
  • 罕见遗传疾病
  • 呼吸系统疾病

第 8 章 mRNA 治疗市场：依最终用途分类

  • 介绍
  • 医院/诊所
  • 研究所

第九章美洲mRNA治疗市场

  • 介绍
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第10章亚太mRNA治疗市场

  • 介绍
  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章 欧洲/中东/非洲mRNA治疗市场

  • 介绍
  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Abogen Biosciences
  • Alnylam Pharmaceuticals, Inc.
  • Arcturus Therapeutics
  • AstraZeneca plc
  • BioNTech SE
  • CRISPR Therapeutics AG
  • Deep Genomics
  • Eli Lilly and Company
  • GSK plc
  • Laronde Inc.
  • Moderna, Inc.
  • Nutcracker Therapeutics, Inc.
  • Sangamo Therapeutics, Inc.
  • Sarepta Therapeutics, Inc.
  • Tracxn Technologies Limited
  • Translate Bio, Inc. by Sanofi SA
Product Code: MRR-205091A88BBD

The mRNA Therapeutics Market was valued at USD 33.82 billion in 2023, expected to reach USD 41.99 billion in 2024, and is projected to grow at a CAGR of 24.65%, to USD 158.20 billion by 2030.

mRNA therapeutics refers to the use of messenger RNA to instruct cells to produce proteins that can treat or prevent disease. This rapidly evolving field leverages the natural process of protein synthesis in human cells to address a variety of health conditions, ranging from infectious diseases, such as COVID-19, to non-communicable diseases like cancer. The necessity of mRNA therapeutics lies in its potential for rapid development, scalability, and versatility, which have already been demonstrated in the swift response to the COVID-19 pandemic with effective vaccines. The primary application and end-use scope encompass vaccinations, cancer immunotherapies, and rare genetic disorders, offering a promising outlook for personalized medicine.

KEY MARKET STATISTICS
Base Year [2023] USD 33.82 billion
Estimated Year [2024] USD 41.99 billion
Forecast Year [2030] USD 158.20 billion
CAGR (%) 24.65%

Market growth in mRNA therapeutics is significantly influenced by technological advancements, increased funding from public and private sectors, and strategic collaborations between biotech firms and pharmaceutical companies. The recent success of mRNA vaccines has spurred interest and investment, leading to potential opportunities in expanding mRNA-based treatments beyond infectious diseases. Recommendations to capitalize on these opportunities include investing in robust R&D infrastructures, forging strategic alliances, and focusing on regulatory pathways to facilitate market entry.

Challenges curbing market growth involve the high cost of development, storage and distribution complexities due to mRNA's inherent instability, and regulatory hurdles in proving long-term safety and efficacy. Additionally, manufacturing capacity constraints and intellectual property disputes present significant barriers.

Innovation and research should target optimization of mRNA stability and delivery systems, improvement in the precision of targeting specific cells or tissues, and reducing production costs. The nature of the mRNA therapeutics market is characterized by rapid technological changes, strong competition, and highly dynamic regulatory requirements. Collaborations with academia and research institutions can provide valuable insights and drive forward-thinking strategies in this highly promising field.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving mRNA Therapeutics Market

The mRNA Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing incidence of chronic and infectious diseases
    • Growing demand for cancer vaccines and treatments
    • Upsurge demand for mRNA therapeutics and proliferation of government initiatives for large scale sequencing projects
  • Market Restraints
    • High cost of research and threat of failure in quantification of mRNA
  • Market Opportunities
    • Significant biotechnology-related research and development (R&D) initiatives and advancements in medical technology
    • Development of personalized therapeutics for cancer with strong pipeline of new products
  • Market Challenges
    • Regulatory concerns and strategies for mRNA therapeutics

Porter's Five Forces: A Strategic Tool for Navigating the mRNA Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the mRNA Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the mRNA Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the mRNA Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the mRNA Therapeutics Market

A detailed market share analysis in the mRNA Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the mRNA Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the mRNA Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the mRNA Therapeutics Market

A strategic analysis of the mRNA Therapeutics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the mRNA Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Abogen Biosciences, Alnylam Pharmaceuticals, Inc., Arcturus Therapeutics, AstraZeneca plc, BioNTech SE, CRISPR Therapeutics AG, Deep Genomics, Eli Lilly and Company, GSK plc, Laronde Inc., Moderna, Inc., Nutcracker Therapeutics, Inc., Sangamo Therapeutics, Inc., Sarepta Therapeutics, Inc., Tracxn Technologies Limited, and Translate Bio, Inc. by Sanofi S.A..

Market Segmentation & Coverage

This research report categorizes the mRNA Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Prophylactic Vaccines, Therapeutic Drugs, and Therapeutic Vaccines.
  • Based on Application, market is studied across Infectious Diseases, Oncology, Rare Genetic Diseases, and Respiratory Diseases.
  • Based on End Use, market is studied across Hospitals & Clinics and Research Organizations.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing incidence of chronic and infectious diseases
      • 5.1.1.2. Growing demand for cancer vaccines and treatments
      • 5.1.1.3. Upsurge demand for mRNA therapeutics and proliferation of government initiatives for large scale sequencing projects
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of research and threat of failure in quantification of mRNA
    • 5.1.3. Opportunities
      • 5.1.3.1. Significant biotechnology-related research and development (R&D) initiatives and advancements in medical technology
      • 5.1.3.2. Development of personalized therapeutics for cancer with strong pipeline of new products
    • 5.1.4. Challenges
      • 5.1.4.1. Regulatory concerns and strategies for mRNA therapeutics
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. mRNA Therapeutics Market, by Type

  • 6.1. Introduction
  • 6.2. Prophylactic Vaccines
  • 6.3. Therapeutic Drugs
  • 6.4. Therapeutic Vaccines

7. mRNA Therapeutics Market, by Application

  • 7.1. Introduction
  • 7.2. Infectious Diseases
  • 7.3. Oncology
  • 7.4. Rare Genetic Diseases
  • 7.5. Respiratory Diseases

8. mRNA Therapeutics Market, by End Use

  • 8.1. Introduction
  • 8.2. Hospitals & Clinics
  • 8.3. Research Organizations

9. Americas mRNA Therapeutics Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific mRNA Therapeutics Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa mRNA Therapeutics Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abogen Biosciences
  • 2. Alnylam Pharmaceuticals, Inc.
  • 3. Arcturus Therapeutics
  • 4. AstraZeneca plc
  • 5. BioNTech SE
  • 6. CRISPR Therapeutics AG
  • 7. Deep Genomics
  • 8. Eli Lilly and Company
  • 9. GSK plc
  • 10. Laronde Inc.
  • 11. Moderna, Inc.
  • 12. Nutcracker Therapeutics, Inc.
  • 13. Sangamo Therapeutics, Inc.
  • 14. Sarepta Therapeutics, Inc.
  • 15. Tracxn Technologies Limited
  • 16. Translate Bio, Inc. by Sanofi S.A.

LIST OF FIGURES

  • FIGURE 1. MRNA THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. MRNA THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL MRNA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES MRNA THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES MRNA THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. MRNA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. MRNA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. MRNA THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL MRNA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. MRNA THERAPEUTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY PROPHYLACTIC VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY RARE GENETIC DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY RESPIRATORY DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES MRNA THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 146. MRNA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 147. MRNA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023